Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 34 | 2021 | 2207 | 2.110 |
Why?
|
| Cognition Disorders | 4 | 2013 | 233 | 1.220 |
Why?
|
| Anti-HIV Agents | 10 | 2018 | 394 | 1.150 |
Why?
|
| Monocytes | 11 | 2018 | 258 | 1.040 |
Why?
|
| Cerebrovascular Disorders | 2 | 2012 | 37 | 0.820 |
Why?
|
| HIV-1 | 8 | 2018 | 678 | 0.680 |
Why?
|
| Middle Aged | 37 | 2021 | 9642 | 0.620 |
Why?
|
| Cognition | 5 | 2018 | 373 | 0.600 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 15 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2018 | 219 | 0.560 |
Why?
|
| Anti-Retroviral Agents | 7 | 2018 | 139 | 0.550 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 40 | 0.540 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 55 | 0.540 |
Why?
|
| Cerebral Cortex | 2 | 2013 | 274 | 0.510 |
Why?
|
| Male | 42 | 2021 | 18870 | 0.510 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 10 | 0.480 |
Why?
|
| Mucuna | 1 | 2013 | 1 | 0.470 |
Why?
|
| Dizziness | 1 | 2013 | 7 | 0.470 |
Why?
|
| Female | 41 | 2021 | 19873 | 0.470 |
Why?
|
| Levodopa | 1 | 2013 | 19 | 0.460 |
Why?
|
| Headache Disorders, Primary | 1 | 2013 | 1 | 0.460 |
Why?
|
| Abdominal Pain | 1 | 2013 | 24 | 0.460 |
Why?
|
| Post-Traumatic Headache | 1 | 2013 | 2 | 0.460 |
Why?
|
| Dementia | 2 | 2014 | 133 | 0.450 |
Why?
|
| Hippocampus | 2 | 2016 | 546 | 0.440 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 19 | 0.430 |
Why?
|
| Brain Injuries | 1 | 2013 | 104 | 0.400 |
Why?
|
| Humans | 44 | 2021 | 34853 | 0.390 |
Why?
|
| Adult | 24 | 2021 | 11034 | 0.390 |
Why?
|
| Viral Load | 4 | 2021 | 300 | 0.390 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 13 | 0.380 |
Why?
|
| Aging | 6 | 2016 | 639 | 0.360 |
Why?
|
| Multilingualism | 1 | 2009 | 31 | 0.350 |
Why?
|
| Cross-Sectional Studies | 16 | 2021 | 2561 | 0.350 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 465 | 0.320 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 628 | 0.310 |
Why?
|
| Central Nervous System | 2 | 2018 | 130 | 0.290 |
Why?
|
| Depression | 1 | 2013 | 664 | 0.290 |
Why?
|
| RNA, Viral | 3 | 2018 | 287 | 0.290 |
Why?
|
| Inflammation | 5 | 2018 | 577 | 0.280 |
Why?
|
| Lipoproteins | 3 | 2014 | 61 | 0.270 |
Why?
|
| Macrophages | 3 | 2014 | 431 | 0.270 |
Why?
|
| Viremia | 2 | 2018 | 40 | 0.270 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2021 | 185 | 0.250 |
Why?
|
| Aged | 9 | 2021 | 6448 | 0.240 |
Why?
|
| Neuropsychological Tests | 5 | 2018 | 255 | 0.240 |
Why?
|
| Hawaii | 9 | 2018 | 1878 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 468 | 0.240 |
Why?
|
| Brain | 3 | 2021 | 1268 | 0.220 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2013 | 12 | 0.220 |
Why?
|
| Interleukin-6 | 2 | 2013 | 140 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 2333 | 0.210 |
Why?
|
| Risk Factors | 8 | 2015 | 3414 | 0.210 |
Why?
|
| Prospective Studies | 3 | 2015 | 1353 | 0.210 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 59 | 0.200 |
Why?
|
| DNA, Viral | 2 | 2013 | 295 | 0.190 |
Why?
|
| Prevalence | 2 | 2017 | 1425 | 0.190 |
Why?
|
| Atrophy | 3 | 2016 | 40 | 0.190 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 224 | 0.190 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 13 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 21 | 0.170 |
Why?
|
| Galectins | 1 | 2018 | 27 | 0.170 |
Why?
|
| Benzoxazines | 1 | 2018 | 46 | 0.170 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 27 | 0.170 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 26 | 0.170 |
Why?
|
| Antigens, CD | 1 | 2018 | 116 | 0.160 |
Why?
|
| Leukoaraiosis | 2 | 2008 | 2 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 135 | 0.160 |
Why?
|
| AIDS Dementia Complex | 3 | 2014 | 107 | 0.160 |
Why?
|
| Erythrocytes | 1 | 2018 | 107 | 0.160 |
Why?
|
| Headache | 1 | 2017 | 18 | 0.150 |
Why?
|
| Neurocysticercosis | 1 | 2017 | 27 | 0.150 |
Why?
|
| Epilepsy | 1 | 2017 | 41 | 0.150 |
Why?
|
| Blood Glucose | 3 | 2014 | 333 | 0.150 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 22 | 0.140 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 34 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 341 | 0.140 |
Why?
|
| Diagnostic Equipment | 1 | 2015 | 3 | 0.140 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 20 | 0.140 |
Why?
|
| Brachial Artery | 1 | 2015 | 31 | 0.140 |
Why?
|
| Brain Ischemia | 2 | 2008 | 179 | 0.140 |
Why?
|
| Amblyopia | 1 | 2015 | 13 | 0.140 |
Why?
|
| Vasodilation | 1 | 2015 | 65 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2016 | 93 | 0.130 |
Why?
|
| Vision Screening | 1 | 2015 | 21 | 0.130 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 26 | 0.130 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 31 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 82 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1056 | 0.130 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 165 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 424 | 0.130 |
Why?
|
| Cyclohexanes | 1 | 2014 | 29 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 43 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 61 | 0.130 |
Why?
|
| Comorbidity | 2 | 2016 | 606 | 0.120 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2014 | 31 | 0.120 |
Why?
|
| Triazoles | 1 | 2014 | 85 | 0.120 |
Why?
|
| Polyneuropathies | 1 | 2013 | 10 | 0.120 |
Why?
|
| Carotid Arteries | 1 | 2013 | 29 | 0.120 |
Why?
|
| Reflex | 1 | 2013 | 31 | 0.120 |
Why?
|
| Cholesterol | 1 | 2014 | 194 | 0.120 |
Why?
|
| Social Work | 1 | 2013 | 45 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2016 | 301 | 0.120 |
Why?
|
| Dopamine Agents | 1 | 2013 | 24 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 66 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2015 | 469 | 0.120 |
Why?
|
| Tension-Type Headache | 1 | 2013 | 1 | 0.120 |
Why?
|
| Migraine Disorders | 1 | 2013 | 6 | 0.110 |
Why?
|
| Niacin | 1 | 2013 | 23 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2013 | 196 | 0.110 |
Why?
|
| Cerebellum | 1 | 2013 | 69 | 0.110 |
Why?
|
| Albuminuria | 1 | 2013 | 76 | 0.110 |
Why?
|
| Calcium | 1 | 2016 | 445 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 608 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2014 | 167 | 0.110 |
Why?
|
| Oxidative Stress | 2 | 2016 | 874 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2012 | 12 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 214 | 0.110 |
Why?
|
| Autonomic Nervous System | 1 | 2012 | 36 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 18 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 94 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2014 | 177 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2017 | 1961 | 0.100 |
Why?
|
| Eating | 1 | 2013 | 152 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 243 | 0.100 |
Why?
|
| Hospitalization | 1 | 2014 | 370 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 126 | 0.100 |
Why?
|
| Psychological Tests | 1 | 2011 | 52 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2014 | 1422 | 0.100 |
Why?
|
| Mitochondria | 1 | 2014 | 454 | 0.100 |
Why?
|
| Vitamin D | 1 | 2013 | 176 | 0.100 |
Why?
|
| Memory | 1 | 2012 | 165 | 0.100 |
Why?
|
| Educational Status | 1 | 2012 | 295 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2013 | 296 | 0.090 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 182 | 0.090 |
Why?
|
| Cell Movement | 1 | 2013 | 545 | 0.090 |
Why?
|
| Logistic Models | 1 | 2013 | 894 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 52 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 859 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 775 | 0.090 |
Why?
|
| Papilledema | 1 | 2009 | 1 | 0.090 |
Why?
|
| Pseudotumor Cerebri | 1 | 2009 | 2 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2014 | 281 | 0.090 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2008 | 2 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 141 | 0.080 |
Why?
|
| Phenotype | 3 | 2016 | 650 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2018 | 628 | 0.080 |
Why?
|
| Vision Disorders | 1 | 2009 | 59 | 0.080 |
Why?
|
| Time Factors | 1 | 2013 | 1681 | 0.080 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 24 | 0.080 |
Why?
|
| Incidence | 1 | 2010 | 882 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 841 | 0.080 |
Why?
|
| Leukocyte Count | 2 | 2018 | 74 | 0.070 |
Why?
|
| Age Factors | 3 | 2018 | 1007 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2016 | 53 | 0.070 |
Why?
|
| Zidovudine | 2 | 2015 | 33 | 0.060 |
Why?
|
| Receptors, IgG | 2 | 2014 | 48 | 0.060 |
Why?
|
| Atherosclerosis | 2 | 2014 | 131 | 0.060 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Neopterin | 1 | 2018 | 11 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2018 | 39 | 0.040 |
Why?
|
| Alkynes | 1 | 2018 | 49 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2014 | 727 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 52 | 0.040 |
Why?
|
| Taenia solium | 1 | 2017 | 9 | 0.040 |
Why?
|
| Blood Pressure | 2 | 2013 | 613 | 0.040 |
Why?
|
| HIV | 1 | 2016 | 97 | 0.040 |
Why?
|
| Los Angeles | 1 | 2017 | 368 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 528 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 56 | 0.030 |
Why?
|
| Stavudine | 1 | 2015 | 13 | 0.030 |
Why?
|
| Thailand | 1 | 2015 | 48 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 20 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 222 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 150 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 206 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 200 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 46 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 61 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 296 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 173 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 27 | 0.030 |
Why?
|
| Oxygen | 1 | 2014 | 193 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 84 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 707 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 416 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 580 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 59 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 341 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 57 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 256 | 0.030 |
Why?
|
| Seasons | 1 | 2013 | 112 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 106 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 1014 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 878 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 325 | 0.030 |
Why?
|
| Gene Expression | 1 | 2014 | 639 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2015 | 1318 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 67 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 968 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4012 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 569 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 248 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1349 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2008 | 49 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 92 | 0.020 |
Why?
|
| Survivors | 1 | 2008 | 126 | 0.020 |
Why?
|
| Linear Models | 1 | 2007 | 253 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 231 | 0.020 |
Why?
|
| Smoking | 1 | 2008 | 903 | 0.010 |
Why?
|
| Child | 1 | 2009 | 2875 | 0.010 |
Why?
|
| Hypertension | 1 | 2008 | 770 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 14307 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 5035 | 0.010 |
Why?
|